Related Experiment Video
Updated: Oct 14, 2025
Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
Published on: December 27, 2017
Platelet Abnormalities in CKD and Their Implications for Antiplatelet Therapy
Constance C F M J Baaten1,2, Jonas R Schröer1, Jürgen Floege3
1Institute for Molecular Cardiovascular Research, University Hospital Rheinisch-Westfälische Technische Hochschule Aachen, Aachen, Germany.
Insights
Patients with chronic kidney disease (CKD) face increased risks of both blood clots and bleeding due to altered platelet function. Understanding these platelet changes is crucial for optimizing antiplatelet therapies in CKD patients.
Area of Science:
- Nephrology
- Hematology
- Cardiology
Background:
- Patients with chronic kidney disease (CKD) have a high risk of cardiovascular and thromboembolic events, often dying from cardiovascular disease.
- Paradoxically, CKD patients also exhibit an increased risk of hemorrhages, complicating therapeutic interventions.
- Platelets play a critical role in hemostasis, and their altered function (hyper- or hyporeactivity) in CKD may underlie these thrombotic and hemorrhagic complications.
Purpose of the Study:
- To review and summarize current knowledge on CKD-induced hemostasis aberrations, focusing on platelet abnormalities.
- To discuss the contribution of altered vascular integrity, coagulation, and red blood cell count to hemostasis dysfunction in CKD.
- To analyze antiplatelet treatment strategies, their risks and benefits (thrombosis vs. bleeding), and clinical outcomes in CKD patients.
Main Methods:
- Literature review and synthesis of existing research on hemostasis and platelet function in CKD.
- Analysis of molecular changes affecting platelet activity in CKD.
- Evaluation of clinical data regarding antiplatelet therapy efficacy and safety in different CKD stages.
Main Results:
- CKD is associated with significant molecular changes leading to altered platelet function, impacting hemostasis.
- Vascular integrity, coagulation pathways, and red blood cell parameters are also affected in CKD, contributing to hemostatic dysregulation.
- Antiplatelet therapy in CKD requires careful risk-benefit assessment due to the dual risk of thrombosis and bleeding, with outcomes varying by CKD stage.
Conclusions:
- Altered platelet activity and hemostasis are key features of CKD, contributing to high cardiovascular and bleeding risks.
- Optimizing antiplatelet therapy in CKD necessitates a deeper understanding of underlying platelet mechanisms.
- Further research into platelet function and tailored antiplatelet strategies is essential for improving clinical outcomes in high-risk CKD patients.
Abstract:
Patients with CKD display a significantly higher risk of cardiovascular and thromboembolic complications, with around half of patients with advanced CKD ultimately dying of cardiovascular disease. Paradoxically, these patients also have a higher risk of hemorrhages, greatly complicating patient therapy. Platelets are central to hemostasis, and altered platelet function resulting in either platelet hyper- or hyporeactivity may contribute to thrombotic or hemorrhagic complications. Different molecular changes have been identified that may underlie altered platelet activity and hemostasis in CKD. In this study, we summarize the knowledge on CKD-induced aberrations in hemostasis, with a special focus on platelet abnormalities. We also discuss how prominent alterations in vascular integrity, coagulation, and red blood cell count in CKD may contribute to altered hemostasis in these patients who are high risk. Furthermore, with patients with CKD commonly receiving antiplatelet therapy to prevent secondary atherothrombotic complications, we discuss antiplatelet treatment strategies and their risk versus benefit in terms of thrombosis prevention, bleeding, and clinical outcome depending on CKD stage. This reveals a careful consideration of benefits versus risks of antiplatelet therapy in patients with CKD, balancing thrombotic versus bleeding risk. Nonetheless, despite antiplatelet therapy, patients with CKD remain at high cardiovascular risk. Thus, deep insights into altered platelet activity in CKD and underlying mechanisms are important for the optimization and development of current and novel antiplatelet treatment strategies, specifically tailored to these patients who are high risk. Ultimately, this review underlines the importance of a closer investigation of altered platelet function, hemostasis, and antiplatelet therapy in patients with CKD.
Related Concept Videos
01:24Chronic Kidney Disease II: Clinical Manifestations
01:25Chronic Kidney Disease I: Introduction
01:28Chronic Kidney Disease III: Interprofessional Care
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Acute Kidney Injury II: Pathophysiology